Ampio Pharmaceuticals Shares Rise 7% After Positive Results for Covid-19 Treatment
1:46 pm ET April 27, 2021 (Dow Jones) Print
By Chris Wack
Ampio Pharmaceuticals Inc. shares were up 7% to $2 Tuesday after the company said it saw positive results in its AP-014 Phase I clinical trial using inhaled Ampion in treating respiratory distress in patients as a result of Covid-19.
The biopharmaceutical company said all patients in the study have now completed treatment, including a follow-up at day 28 after treatment.
Ampio said the study not only met its primary endpoint, the final data showed an even greater improvement in all-cause mortality over patients treated using standard of care than initially reported. Mortality in the SOC group was 24%, while that in the group treated with SOC and Ampion was only 5%, a 78% improvement in all-cause mortality. Preliminary results had been reported in March as 21% for SOC and 8% for Ampion, or a 62% improvement.
The study showed patients who received Ampion required less hospitalization time, the company said. The average hospital length of stay was four days less for the Ampion group compared with patients receiving standard of care. Patients treated with Ampion were either stable or showed improvement on a scale of clinical improvement compared to patients treated using SOC. By day 5, 89% of patients who received Ampion were stable or had improvement compared to 77% of patients who received SOC.
Ampio said the treatment was safe and well-tolerated in all patients. There were no remarkable adverse events with Ampion treatment, and no drug-related serious adverse events were reported
Ampio also said it had received a positive response from the U.S. Food and Drug Administration on its plans for a Phase III trial utilizing intra-articular injection of Ampion for treating osteoarthritis of the knee. The trial was paused in early 2020, along with over 1,000 other trials, because of the Covid-19 pandemic, and the FDA was providing guidance on steps for moving forward with the trial.
Volume for the stock was 4.4 million shares at 1:35 p.m. ET, compared with 65-day average volume of 2.8 million shares.
Write to Chris Wack at
chris.wack@wsj.com (END) Dow Jones Newswires
April 27, 2021 13:46 ET (17:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
(Tagesgewinn über 30 %) mehr als bestätigt worden. Massiver Ausbruch wie ein Vulkan mit entsprechend hohem Volumen von rund 5 Millionen Titel, bis anhin viel tiefer.